Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19217507 | 0.96 | ESR1 (0.44) | ESR1HDAC3HDAC1HDAC11HDAC8 | |
| SCHEMBL21507866 | 0.96 | ESR1 (0.41) | ESR1HDAC3HDAC1HDAC11HDAC8 | |
| SCHEMBL18949946 | 0.95 | ESR1 (0.40) | ESR1HDAC3HDAC1HDAC11HDAC8 | |
| SCHEMBL18542136 | 0.93 | ESR1 (0.41) | ESR1HDAC3HDAC1HDAC11HDAC8 | |
| SCHEMBL19424088 | 0.93 | ESR1 (0.41) | ESR1HDAC3HDAC1HDAC11HDAC8 | |
| SCHEMBL19204390 | 0.93 | ESR1 (0.41) | ESR1HDAC3HDAC1HDAC11HDAC8 | |
| SCHEMBL21191577 | 0.93 | ESR1 (0.41) | ESR1HDAC3HDAC1HDAC11HDAC8 | |
| SCHEMBL9557316 | 0.93 | ESR1 (0.41) | ESR1HDAC3HDAC1HDAC11HDAC8 | |
| SCHEMBL18542125 | 0.93 | ESR1 (0.41) | ESR1HDAC3HDAC1HDAC11HDAC8 | |
| SCHEMBL9557621 | 0.93 | ESR1 (0.41) | ESR1HDAC3HDAC1HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-20220009906-A1 | ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-13 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | HAVCR2, HDGF, HCCS | ESR1 1800/4885HDAC3 602/4885HDAC1 395/4885 |
| US-20220009906-A1 | ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | GRK2, GRK3, GRK4 | ESR1 3802/4885HDAC3 337/4885HDAC1 371/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | ESR1 1662/4885HDAC3 786/4885HDAC1 519/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | ESR1 1662/4885HDAC3 786/4885HDAC1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.